Primary prevention of cardiovascular disease: The past, present, and future of blood pressure- and cholesterol-lowering treatments

1. Kannel WB, Dawber TR, Kagan A, Revotskie N, Stokes J 3rd. Factors of risk in the development of coronary heart disease—six year follow-up experience: the Framingham Study. Ann Intern Med. 1961 Jul;55:33–50. 13751193

2. Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. JAMA. 1977 Jan 17;237(3):255–61. 576159

3. Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017 Nov 7: Epub ahead of print.

4. Karmali KN, Lloyd-Jones DM, van der Leeuw J, Goff DC Jr, Rahimi K, Yusuf S, et al. Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. PLoS Med. 2018;15(3): e1002538. doi: 10.1371/journal.pmed.2002538

5. Leening MJG, Cook NR, Ridker PM. Should we reconsider the role of age in treatment allocation for primary prevention of cardiovascular disease? Eur Heart J. 2017 May 21;38(20):1542–7. doi: 10.1093/eurheartj/ehw287 27357357

6. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S1–45. doi: 10.1161/01.cir.0000437738.63853.7a 24222016

7. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D’Agostino RB, Gibbons R, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Jun 24;129(25 Suppl 2):S49–73. doi: 10.1161/01.cir.0000437741.48606.98 24222018

8. JBS3 Board. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart. 2014 Apr;100 Suppl 2:ii1–ii67.

9. Leening MJG, Berry JD, Allen NB. Lifetime perspectives on primary prevention of atherosclerotic cardiovascular disease. JAMA. 2016 Apr 12;315(14):1449–50. doi: 10.1001/jama.2016.1654 26999711

10. Sniderman AD, Toth PP, Thanassoulis G, Pencina MJ, Furberg CD. Taking a longer term view of cardiovascular risk: the causal exposure paradigm. BMJ. 2014;348:g3047. doi: 10.1136/bmj.g3047 24850828

11. Allen NB, Siddique J, Wilkins JT, Shay C, Lewis CE, Goff DC, et al. Blood pressure trajectories in early adulthood and subclinical atherosclerosis in middle age. JAMA. 2014 Feb 5;311(5):490–7. doi: 10.1001/jama.2013.285122 24496536

12. Pavlović J, Greenland P, Deckers JW, Brugts JJ, Kavousi M, Dhana K, et al. Comparison of ACC/AHA and ESC guideline recommendations following trial evidence for statin use in primary prevention of cardiovascular disease: results from the population-based Rotterdam Study. JAMA Cardiol. 2016 Sep 1;1(6):708–13. doi: 10.1001/jamacardio.2016.1577 27439175

13. Greenland P. Cardiovascular guideline skepticism vs lifestyle realism? JAMA. 2018 Jan 9;319(2):117–8. doi: 10.1001/jama.2017.19675 29242938

14. Greenland P, Peterson ED. The new 2017 ACC/AHA guidelines "up the pressure" on diagnosis and treatment of hypertension. JAMA. 2017 Dec 5;318(21):2083–4. doi: 10.1001/jama.2017.18605 29159417

15. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J. 2016 Aug 1;37(29):2315–81. doi: 10.1093/eurheartj/ehw106 27222591

16. Anderson TJ, Gregoire J, Pearson GJ, Barry AR, Couture P, Dawes M, et al. 2016 Canadian Cardiovascular Society guidelines for the management of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2016 Nov;32(11):1263–82. doi: 10.1016/j.cjca.2016.07.510 27712954

17. US Preventive Services Task Force. Statin use for the primary prevention of cardiovascular disease in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016 Nov 15;316(19):1997–2007. doi: 10.1001/jama.2016.15450 27838723

18. Pavlović J, Greenland P, Deckers JW, Kavousi M, Hofman A, Ikram MA, et al. Assessing gaps in cholesterol treatment guidelines for primary prevention of cardiovascular disease based on available randomised clinical trial evidence: the Rotterdam Study. Eur J Prev Cardiol. 2018 Mar 1;25(4):420–31. doi: 10.1177/2047487317743352 29171772

19. Ferket BS, van Kempen BJH, Heeringa J, Spronk S, Fleischmann KE, Nijhuis RLG, et al. Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study. PLoS Med. 2012;9(12):e1001361. doi: 10.1371/journal.pmed.1001361 23300388

20. Thanassoulis G, Williams K, Altobelli KK, Pencina MJ, Cannon CP, Sniderman AD. Individualized statin benefit for determining statin eligibility in the primary prevention of cardiovascular disease. Circulation. 2016 Apr 19;133(16):1574–81. doi: 10.1161/CIRCULATIONAHA.115.018383 26945047

21. Dorresteijn JAN, Visseren FLJ, Ridker PM, Wassink AMJ, Paynter NP, Steyerberg EW, et al. Estimating treatment effects for individual patients based on the results of randomised clinical trials. BMJ. 2011;343:d5888. doi: 10.1136/bmj.d5888 21968126

22. van der Leeuw J, Ridker PM, van der Graaf Y, Visseren FLJ. Personalized cardiovascular disease prevention by applying individualized prediction of treatment effects. Eur Heart J. 2014 Apr;35(13):837–43. doi: 10.1093/eurheartj/ehu004 24513790